BIRC5 and chronic kidney disease: Altogether, our study revealed the critical role of a common TP53RK/Birc5 signaling pathway in promoting both p‐EMT and interstitial fibroblast proliferation during CKD development, and it established the translational potential of TP53RK and Birc5 inhibitors as therapeutic agents against CKDs.